Quantbot Technologies LP acquired a new position in Diplomat Pharmacy Inc (NYSE:DPLO) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 35,907 shares of the company’s stock, valued at approximately $696,000.
Several other institutional investors have also recently modified their holdings of DPLO. Public Employees Retirement Association of Colorado increased its position in Diplomat Pharmacy by 142.2% during the third quarter. Public Employees Retirement Association of Colorado now owns 6,307 shares of the company’s stock worth $122,000 after acquiring an additional 3,703 shares during the period. Cornerstone Wealth Management LLC bought a new position in Diplomat Pharmacy during the third quarter worth $340,000. United Services Automobile Association bought a new position in Diplomat Pharmacy during the second quarter worth $210,000. D.A. Davidson & CO. bought a new position in Diplomat Pharmacy during the second quarter worth $215,000. Finally, UBS Group AG increased its position in Diplomat Pharmacy by 186.4% during the first quarter. UBS Group AG now owns 8,491 shares of the company’s stock worth $171,000 after acquiring an additional 5,526 shares during the period. Institutional investors and hedge funds own 85.24% of the company’s stock.
Several equities research analysts have issued reports on the stock. ValuEngine lowered shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a report on Wednesday, September 12th. Morgan Stanley lowered their price target on shares of Diplomat Pharmacy from $20.00 to $18.00 and set an “equal weight” rating on the stock in a report on Monday. Robert W. Baird raised shares of Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and boosted their price target for the company from $10.00 to $15.00 in a report on Friday. Wells Fargo & Co lowered their price target on shares of Diplomat Pharmacy from $23.00 to $16.00 and set a “market perform” rating on the stock in a report on Thursday, November 8th. Finally, Zacks Investment Research raised shares of Diplomat Pharmacy from a “sell” rating to a “hold” rating in a report on Tuesday, November 6th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $24.70.
DPLO opened at $14.92 on Friday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.66 and a current ratio of 0.95. Diplomat Pharmacy Inc has a twelve month low of $13.31 and a twelve month high of $28.74. The stock has a market capitalization of $1.17 billion, a PE ratio of 17.76 and a beta of 0.88.
Diplomat Pharmacy (NYSE:DPLO) last posted its earnings results on Tuesday, November 6th. The company reported $0.01 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by ($0.21). Diplomat Pharmacy had a return on equity of 5.31% and a net margin of 0.04%. The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.42 billion. During the same period in the previous year, the company posted $0.01 EPS. The firm’s revenue for the quarter was up 22.0% compared to the same quarter last year. Analysts expect that Diplomat Pharmacy Inc will post 0.79 earnings per share for the current year.
In related news, Director Philip R. Hagerman sold 57,500 shares of the company’s stock in a transaction dated Tuesday, September 11th. The shares were sold at an average price of $19.21, for a total transaction of $1,104,575.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Philip R. Hagerman sold 209,367 shares of the company’s stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $19.07, for a total transaction of $3,992,628.69. The disclosure for this sale can be found here. 24.70% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2018/12/07/35907-shares-in-diplomat-pharmacy-inc-dplo-purchased-by-quantbot-technologies-lp.html.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Read More: Rule of 72
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.